Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: September 2009

Section 2 - Pathophysiology

References

AdamsHP Jr., LoveBB, JacobyMR. Arterial dissections. In: GinsbergMD, BogousslavskyJ, eds. Cerebrovascular Disease. Oxford: Blackwell Science, 1998; 1430–46.
AdamsRD, Vander EeckenHM. Vascular diseases of the brain. Ann Rev Med 1953; 4: 213–52.
AltieriM, Di PieroV, PasquiniMet al. Delayed poststroke dementia: a 4-year follow-up study. Neurology 2004; 62: 2193–7.
AmarencoP, CohenA, TzourioC, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331: 1474–9.
BarbaR, Martinez-EspinosaS, Rodriguez-GarciaE, et al. Poststroke dementia: clinical features and risk factors. Stroke 2000; 31: 1494–501.
Bastos LeiteAJ, van der FlierWM, van StraatenEC, et al. Infratentorial abnormalities in vascular dementia. Stroke 2006; 37: 105–10.
BeckerH, DeschH, HackerH, PenczA. CT fogging effect with ischemic cerebral infarcts. Neuroradiology 1979; 18: 185–92.
BergerMS, WilsonCB. Intracranial dissecting aneurysms of the posterior circulation. Report of six cases and review of the literature. J Neurosurg 1984; 61: 882–94.
BowlerJV, SteenhuisR, HachinskiV. Conceptual background to vascular cognitive impairment. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3): S30–7.
BrandtT, OrberkE, WeberR, et al. Pathogenesis of cervical artery dissections. Association with connective tissue abnormalities. Neurology 2001; 57: 24–30.
CaplanLR. Dilatative arteriopathy (dolichoectasia). What is known and not known. Ann Neurol 2005; 57: 469–71.
CensoriB, ManaraO, AgostinisC, et al. Dementia after first stroke. Stroke 1996; 27: 1205–10.
ChalelaJA, KidwellCS, NentwichLM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007; 369: 293–8.
ChavesC, EstolC, EsnaolaM, et al. Spontaneous intracranial internal carotid artery dissection. Arch Neurol 2002; 59: 977–81.
ChuaquiR, TapiaJ. Histologic assessment of the age of recent brain infarcts in man. Neuropathol Exp Neurol 1993; 52: 481–9.
Cordoliani-MackowiakMA, HénonH, PruvoJP, et al. Poststroke dementia: the influence of hippocampal atrophy. Arch Neurol 2003; 60: 565–90.
del SerT, BermejoF, PorteraA, et al. Vascular dementia. A clinicopathological study. J Neurol Sci 1990; 96: 1–17.
del SerT, BarbaR, MorinM, et al. Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke 2005; 36: 2670–5.
del ZoppoGJ. Microvascular changes during cerebral ischemia and reperfusion. Cerebrovasc Brain Metab Rev 1994; 6: 47–96.
DesmondDW, MoroneyJT, PaikMC, et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000; 54: 1124–31.
DesmondDW, MoroneyJT, SanoM, SternY. Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 2002; 33: 2254–60.
EckertB, ZeumerH. Brain computed tomography. In: GinsbergMDBogousslavskyJ, eds. Cerebrovascular Disease. Oxford: Blackwell Science, 1998; 1241–64.
EllisonD, GatterK, HeryetA, EsiriM. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol 1993; 46: 37–40.
ErkinjunttiT, HaltiaM, PaloJ, et al. Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatry 1988; 51: 1037–44.
ErkinjunttiT, InzitariD, PantoniL, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59: 23–30.
FarrellMA, GilbertJJ, KaufmannJC. Fatal intracranial arterial dissection: clinical pathological correlation. J Neurol Neurosurg Psychiatry 1985; 48: 111–21.
FisherM, FiemanS. Geometric factors of the bifurcation in carotid atherogenesis. Stroke 1990; 21: 267–71.
GarciaJH, YoshidaY, ChenH, et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol 1993; 142: 623–35.
GarciaJH, LiuKF, HoKL. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke 1995; 26: 636–42.
GarciaJH, AndersonML. Circulatory disorders and their effects on the brain. In: DavisRL and RobertsonDM, eds. Textbook of Neuropathology. Baltimore: Williams & Wilkins, 1997; 715–822.
HachinskiVC, LassenNA, MarshallJ. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2: 207–10.
HachinskiVC, IliffLD, ZilhkaE, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632–7.
HankeyGJ. Necrotizing and granulomatous angiitis of the CNS. In: GinsbergMD, BogousslavskyJ, eds. Cerebrovascular Disease. Oxford: Blackwell Science, 1998; 1647–83.
HénonH. Pre-stroke dementia: prevalence and associated factors. Cerebrovasc Dis 2000; 10 (Suppl 4), 45–8.
HénonH, DurieuI, GuerouaouD, et al. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001; 57: 1216–22.
HénonH, PasquierF, LeysD. Poststroke dementia. Cerebrovasc Dis 2006; 22: 61–70.
IkezakiK, FukuiM. Definition (guidelines). In: IkezakiK, LoftusCM, eds. Moyamoya Disease. Illinois: American Association of Neurological Surgeons (AANS) Publications, 2001; 13–22.
InzitariD, Di CarloA, PracucciG, et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998; 29: 2087–93.
IvanCS, SeshadriS, BeiserA, et al. Dementia after stroke: the Framingham study. Stroke 2004; 35: 1264–68.
JellingerKA. Understanding the pathology of vascular cognitive impairment. J Neurol Sci 2005; 229–230: 57–63.
JonesEF, KalmanJM, CalafioreP, et al. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke 1995; 26: 218–24.
JudgeRD, CurrierRD, GracieWA, FigleyMM. Takayasu’s arteritis and the aortic arch syndrome. Am J Med 1962; 32: 379–92.
KatzensteinAL, CarringtonCB, LiebowAA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979; 43: 360–73.
KhatriP, WechslerLR, BroderickJP. Intracranial hemorrhage associated with revascularization therapies. Stroke 2007; 38: 431–40.
Kleinschmidt-DeMastersBK, FilleyCM, BitterMA. Central nervous system angiocentric, angiodestructive T-cell lymphoma (lymphomatoid granulomatosis). Surg Neurol 1992; 37: 130–7.
KullerLH, LopezOL, JagustWJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 2005; 64: 1548–52.
LeysD, HenonH, Mackowiak-CordolianiMA, PasquierF. Poststroke dementia. Lancet Neurol 2005; 4: 752–9.
LinJH, LinRT, TaiCT, et al. Prediction of poststroke dementia. Neurology 2003; 61: 343–8.
LiuCK, MillerBL, CummingsJL, et al. A quantitative MRI study of vascular dementia. Neurology 1992; 42: 138–43.
LoebC, GandolfoC, BinoG. Intellectual impairment and cerebral lesions in multiple cerebral infarcts. A clinical-computed tomography study. Stroke 1988; 19: 560–5.
LucasC, MoulinT, DeplanqueD, et al. Stroke patterns of internal carotid artery dissection in 40 patients. Stroke 1998; 29: 2646–48.
MadureiraS, GuerreiroM, FerroJM. Dementia and cognitive impairment three months after stroke. Eur J Neurol 2001; 8: 621–7.
MasdeuJC, IriniaP, AsenbaumS, et al. EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force. Eur J Neurol 2006; 13: 1271–83.
MasudaJ, OgataJ, ButaniC. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 1993; 24: 1960–67.
MasudaJ, OgataJ, YamaguchiT (2004). Moyamoya disease. In: JP Mohr, DW Choi, JC Grotta, B Weir, PA Wolf, eds. Stroke: Pathophysiology, diagnosis, and management. Philadelphia: Churchill Livingstone, 2004; 603–18.
McKusickVA. A form of vascular disease relatively frequent in the Orient. Am Heart J 1962; 63: 57–64.
MielkeR, HerholzK, GrondM, et al. Severity of vascular dementia is related to volume of metabolically impaired tissue. Arch Neurol 1992; 49: 909–13.
MitsiasP, LevineSR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 1994; 44: 385–93.
NishimuraM, SatohK, SugaM, OdaM. Cerebral angio- and neuro-Behcet’s syndrome: neuroradiological and pathological study of one case. J Neurol Sci 1991; 106: 19–24.
NumanoF, OkawaraM, InomataH, KobayashiY. Takayasu’s arteritis. Lancet 2000; 356: 1023–5.
OgataJ, MasudaJ, NishikawaM, YokotaT. Sclerosed peripheral-artery aneurysm in moyamoya disease. Cerebrovasc Dis 1996; 6: 248–9.
OgataJ, PantoniL. Neuropathology of ischemic brain damage. In: AminoffM, BollerF, SwaabD, eds. Handbook of Clinical Neurology, 3rd Series. Amsterdam: Elsevier. In press.
PantoniL. Subtypes of vascular dementia and their pathogenesis: a critical overview. In: BowlerJV, HachinskiV, eds. Vascular Cognitive Impairment-preventable Dementia. New York: Oxford University Press, 2003; 217–29.
PantoniL, BasileAM, RomanelliM, et al. Abulia and cognitive impairment in two patients with capsular genu infarct. Acta Neurol Scand 2001; 104: 185–90.
PantoniL, Sarti. C, AlafuzoffI, et al. Postmortem examination of vascular lesions in cognitive impairment. A survey among neuropathological services. Stroke 2006; 37: 1005–9.
PasquierF, LeysD. Why are stroke patients prone to develop dementia?J Neurol 1997; 244: 135–42.
PohjasvaaraT, ErkinjunttiT, YlikoskiR, et al. Clinical determinants of poststroke dementia. Stroke 1998; 29: 75–81.
PohjasvaaraT, MantylaR, AronenHJ, et al. Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort. J Neurol Neurosurg Psychiatry 1999; 67: 742–8.
PohjasvaaraT, MantylaR, SalonenO, et al. How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol 2000a; 57: 1295–300.
PohjasvaaraT, MantylaR, SalonenO, et al. MRI correlates of dementia after first clinical ischemic stroke. J Neurol Sci 2000b; 181: 111–7.
RajamaniK, FisherM, FisherM. In: GinsbergMD, BogousslavskyJ, eds. Cerebrovascular Disease. Oxford: Blackwell Science, 1998; 308–18.
RasquinSM, VerheyFR, van OostenbruggeRJ, et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry 2004; 75: 1562–7.
RomanGC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003; 51: S296–304.
RomanGC, TatemichiTK, ErkinjunttiT, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60.
RosenbergMR, ParshleyM, GibsonS, WernickR. Central nervous system polyarteritis nodosa. West J Med 1990; 153: 553–6.
SachdevPS, BrodatyH, ValenzuelaMJ, et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord 2006; 21: 275–83.
ScheltensP, FoxN, BarkhofF, De CarliC. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002; 1: 13–21.
SchievinkWI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med 2001; 344: 898–906.
SchievinkWI, MokriB, PiepgrasDG. Spontaneous dissections of cervicocephalic arteries in childhood and adolescence. Neurology 1994; 44: 1607–12.
SchneiderJA, WilsonRS, CochranEJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003; 60: 1082–8.
SerdarogluP. Behcet’s disease and the nervous system. J Neurol 1998; 245: 197–205.
StrongJP. Atherosclerotic lesions. Natural history, risk factors, and topography. Arch Pathol Lab Med 1992; 116: 1268–75.
TangWK, ChanSS, ChiuHF, et al. Frequency and determinants of poststroke dementia in Chinese. Stroke 2004; 35: 930–5.
TatemichiTK, DesmondDW, MayeuxR, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992; 42: 1185–93.
TatemichiTK, DesmondDW, ProhovnikI. Strategic infarcts in vascular dementia. A clinical and brain imaging experience. Arzneimittelforschung 1995; 45: 371–85.
TomlinsonBE, BlessedG, RothM. Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205–42.
TrevesTA, AronovichBD, BornsteinNM, KorczynAD. Risk of dementia after a first-ever ischemic stroke: a 3 year longitudinal study. Cerebrovasc Dis 1997; 7: 48–52.
van der FlierWM, ScheltensP. Use of laboratory and imaging investigations in dementia. J Neurol Neurosurg Psychiatry 2005; 76 (Suppl. 5): v45–52.
VinijchaikulK. Primary arteritis of the aorta and its major branches (Takayasu’s arteriopathy). A clinicopathologic autopsy study of eight cases. Am J Med 1967; 43: 15–27.
von KummerR, Meyding-LamadeU, ForstingM, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. Am J Neuroradiol 1994; 15: 9–15.
WarachS, ChienD, LiW, et al. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology 1992; 42: 1717–23.
WolfeN, BabikianVL, LinnRT, et al. (1994). Are multiple cerebral infarcts synergistic?Arch Neurol 51: 211–5.
ZhouDH, WangJY, LiJ, et al. Study on frequency and predictors of dementia after ischemic stroke: the Chongqing stroke study. J Neurol 2004; 251: 421–7.
ZhouDH, WangJY, LiJ, et al. Frequency and risk factors of vascular cognitive impairment three months after ischemic stroke in China: the Chongqing stroke study. Neuroepidemiology 2005; 24: 87–95.

References

AkatsuH, TakahashiM, MatsukawaN, et al. Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital. J Neurol Sci 2002; 196: 63–9.
BabikianV, RopperAH.Binswanger’s disease: a review. Stroke 1987; 18: 2–12.
BallardC, McKeithI, O’BrienJ, et al. Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes. Dementia Geriatr Cogn Disord 2000; 11: 59–65.
Benhaiem-SigauxN, GrayF, GherardiR, RoucayrolAM, PoirierJ.Expanding cerebellar lacunes due to dilatation of the perivascular space associated with Binswanger’s subcortical arteriosclerotic encephalopathy. Stroke 1987; 18: 1087–92.
BerriosGE, FreemanHL. Alzheimer and the dementia. In: BerriosGE, ed. Eponymists in Medicine Series. London: Royal Society of Medicine Services, 1991; 69–76.
BornebroekM, HaanJ, RoosRA.Hereditary cerebral hemorrhage with amyloidosis – Dutch type (HCHWA-D): a review of the variety in phenotypic expression. Amyloid 1999; 6: 215–24.
BrunA.Pathology and pathophysiology of cerebrovascular dementia: pure subgroups of obstructive and hypoperfusive etiology. Dementia 1994; 5: 145–7.
ChabriatH, VahediK, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995; 346: 934–9.
ChabriatH, LevyC, TailliaH, et al. Patterns of MRI lesions in CADASIL. Neurology 1998; 51: 452–7.
ChuiHC, VictoroffJI, MargolinD, JagustW, ShankleR, KatzmanR.Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473–80.
CohenDL, HederaP, PremkumarDR, FriedlandRP, KalariaRN.Amyloid-beta protein angiopathies masquerading as Alzheimer’s disease?Ann NY Acad Sci 1997; 826: 390–5.
CummingsJL.Frontal–subcortical circuits and human behavior. Arch Neurol 1993; 50: 873–80.
CummingsJL.Vascular subcortical dementias: clinical aspects. Dementia 1994; 5: 177–80.
DesmondDW, ErkinjunttiT, SanoM, et al. The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3): S21–9.
DichgansM, MayerM, UttnerI, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998; 44: 731–9.
ErkinjunttiT, HaltiaM, PaloJ, SulkavaR, PaetauA.Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatry 1988; 51: 1037–44.
ErkinjunttiT, BowlerJV, DeCarliCS, et al. Imaging of static brain lesions in vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3): S81–90.
ErkinjunttiT, KurzA, GauthierS, BullockR, LilienfeldS, DamarajuCV.Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–90.
ErkinjunttiT, KalariaR.Vascular cognitive impairment. In: GrowdonJ, RossorM, eds. The Dementias. Oxford: Elsevier, 2006.
EsiriMM, WilcockGK, MorrisJH.Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997; 63: 749–53.
EsiriMM, NagyZ, SmithMZ, BarnetsonL, SmithAD.Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999; 354: 919–20.
GoldG, GiannakopoulosP, Montes-Paixao JuniorC, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997; 49: 690–4.
GoldG, BourasC, CanutoA, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 2002; 159: 82–7.
GouldDB, PhalanFC, van MilSE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354: 1489–96.
GouldDB, Cerebral amyloid angiopathy and vessel dysfunction. Cerebrovasc Dis 2002; 13 (Suppl 2): 42–7.
GouldDB, GurolME, RosandJ, SmithEE.Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35: 2616–19.
HaanJ, LanserJB, ZijderveldI, van der DoesIG, RoosRA.Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Archives of Neurology 1990; 47: 965–7.
HagelC, GrodenC, NiemeyerR, StavrouD, ColmantHJ.Subcortical angiopathic encephalopathy in a German kindred suggests an autosomal dominant disorder distinct from CADASIL. Acta Neuropathol (Berl) 2004; 108: 231–40.
HaglundM, EnglundE.Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy – a histopathological assessment. Dementia Geriatr Cogn Disord 2002; 14: 161–6.
HeymanA, FillenbaumGG, Welsh-BohmerKA, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer’s disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer’s Disease. Neurology 1998; 51: 159–62.
HoK-L, GarciaJH. Neuropathology of the small blood vessels in selected disease of the cerebral white matter. In: PantoniL, InzitariD,WallinA, eds. The Matter of White Matter, Vol 10. Utrecht: The Netherlands Academic Pharmaceutical Productions, 2000; 247–73.
HuletteC, NochlinD, Mckeel D, et al. Clinical–neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997; 48: 668–72.
JellingerKA.Vascular–ischemic dementia: an update. J Neural TransmSuppl 2002; 62: 1–23.
.JellingerKA.The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol (Berl) 2007; 113: 349–88.
JenJ, CohenAH, YueQ, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49: 1322–30.
KalariaRN.Advances in molecular genetics and pathology of cerebrovascular disorders. Trends Neurosci 2001; 24: 392–400.
KalariaRN, HederaP.Differential degeneration of the cerebral microvasculature in Alzheimer’s disease. Neuroreport 1995; 6: 477–80.
KalariaRN, BallardC.Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3): S115–23.
KalariaRN, BallardC.Stroke and cognition. Curr Atherosclerosis Rep 2001; 3: 334–9.
KalariaRN, KennyRA, BallardCG, PerryR, InceP, PolvikoskiT.Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004; 226: 75–80.
KalimoH, KasteM, HaltiaM. Vascular diseases. In: GrahamDI, LantosPL, eds. Greenfield’s Neuropathology. London: Arnold 2002a; 281–355.
KalimoH, RuchouxMM, ViitanenM, KalariaRN.CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol 2002b; 12: 371–84.
KalimoH, KalariaRN. Hereditary forms of vascular dementia. In: KalimoH, ed. Cerebrovascular Diseases, Pathology & Genetics, Vol 5. Basel: ISN Neuropath Press, 2005: 324–84.
KerteszA, ClydesdaleS.Neuropsychological deficits in vascular dementia vs Alzheimer’s disease. Frontal lobe deficits prominent in vascular dementia. Arch Neurol 1994; 51: 1226–31.
KovariE, GoldG, HerrmannFR, et al. Cortical microinfarcts and demyelination significantly affect cognition in brain aging. Stroke 2004; 35: 410–4.
LammieGA.Pathology of small vessel stroke. Br Med Bull 2000; 56: 296–306.
Lesnik ObersteinSA, van den BoomR, van Buchem MA, et al. Cerebral microbleeds in CADASIL. Neurology 2001; 57: 1066–70.
MahlerME, CummingsJL.Behavioral neurology of multi-infarct dementia. Alzheimer Dis Assoc Disord 1991; 5: 122–30.
NatteR, Maat-SchiemanML, HaanJ, BornebroekM, RoosRA, van DuinenSG.Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 2001; 50: 765–72.
NolanKA, LinoMM, SeligmannAW, BlassJP.Absence of vascular dementia in an autopsy series from a dementia clinic. J Am Geriatr Soc 1998; 46: 597–604.
O’BrienJT.Vascular cognitive impairment. Am J Geriatr Psychiatry 2006; 14: 724–33.
O’BrienJT, ErkinjunttiT, ReisbergB, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2: 89–98.
OpherkC, PetersN, HerzogJ, LuedtkeR, DichgansM.Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 2004; 127: 2533–9.
OphoffRA, DeYoungJ, ServiceSK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet 2001; 69: 447–53.
PavlovicAM, Zidverc-TrajkovicJ, MilovicMM, et al. Cerebral small vessel disease in pseudoxanthoma elasticum: three cases. Can J Neurol Sci 2005; 32: 115–18.
PillonB, DeweerB, AgidY, DuboisB.Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993; 50: 374–9.
PremkumarDR, CohenDL, HederaP, FriedlandRP, KalariaRN.Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol 1996; 148: 2083–95.
RomanGC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86: 477–99.
RomanGC, TatemichiTK, ErkinjunttiT, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60.
RomanGC, ErkinjunttiT, WallinA, PantoniL, ChuiHC.Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426–36.
RichardsA, van den MaagdenbergAM, JenJC, et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39: 1068–70.
RosenWG, TerryRD, FuldPA, KatzmanR, PeckA.Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486–8.
RossiR, JoachimC, et al. Association between subcortical vascular disease on CT and neuropathological findings. Int J Geriatr Psychiatry 2004; 19: 690–5.
RuchouxMM, GuerouaouD, VandenhauteB, PruvoJP, VermerschP, LeysD.Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol (Berl) 1995; 89: 500–12.
RuchouxMM, MaurageCA.CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 1997; 56: 947–64.
SachdevPS, BrodatyH, ValenzuelaMJ, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004; 62: 912–9.
SarazinM, AmarencoP, MikolJ, DimitriD, LotG, BousserMG.Reversible leukoencephalopathy in cerebral amyloid angiopathy presenting as subacute dementia. Eur J Neurol 2002; 9: 353–8.
SinghalS, BevanS, BarrickT, RichP, MarkusHS.The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004; 127: 2031–8.
SnowdonDA, GreinerLH, MortimerJA, RileyKP, GreinerPA, MarkesberyWR.Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813–17.
SouranderP, WalinderJ.Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol (Berl) 1977; 39: 247–54.
SuterO-C, SunthornT, KraftsikR, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002; 33: 1986–92.
TerwindtGM, HaanJ, OphoffRA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud’s phenomenon. Brain 1998; 121 (Pt 2): 303–16.
TraykovL, BaudicS, ThibaudetM-C, RigaudA-S, SmaggheA, BollerF.Neuropsychological deficit in early subcortical vascular dementia: comparison to Alzheimer’s disease. Dementia Geriatr Cogn Disord 2002; 14: 26–32.
VahediK, MassinP, GuichardJP, et al. Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy. Neurology 2003; 60: 57–63.
van den BoomR, Lesnick ObersteinSA, van den Berg-HuysmansAA, FerrariMD, van BuchemMA, HaanJ.Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: structural MR imaging changes and apolipoprotein E genotype. Am J Neuroradiol 2006; 27: 359–62.
VerreaultS, JoutelA, RiantF, et al. A novel hereditary small vessel disease of the brain. Ann Neurol 2006; 59: 353–7.
VintersHV.Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311–24.
VintersHV, EllisWG, ZarowC, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000; 59: 931–45.
VonsattelJP, MyersRH, Hedley-WhyteET, RopperAH, BirdED, RichardsonEP, Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991; 30: 637–49.
WallinA, BlennowK.The clinical diagnosis of vascular dementia. Dementia 1994; 5: 181–4.
WhiteL, PetrovitchH, HardmanJ, et al. Cerebrovascular pathology and dementia in autopsied Honolulu–Asia Aging Study participants. Ann NY Acad Sci 2002; 977: 9–23.

References

BinswangerO.Die Abgrenzung der allgemeinen progressiven Paralyse. Berl Klin Wochenschr 1894; 31: 1103–05, 1137–9, 1180–6.
BowlerJ, GorelickP.Advances in vascular cognitive impairment 2006. Stroke 2007; 38: 241–4.
BrustJ.Vascular dementia is overdiagnosed. Arch Neurol 1988; 45: 799–801.
BurtonE, McKeithI, BurnD, et al. Progression of white matter hyperintensities in Alzheimer disease, dementia with Lewy bodies, and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 2006; 14: 842–9.
ChabriatH, PappataS, PouponC, et al. Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke 1999; 30: 2637–43.
ChuiH, VictoroffJ, MargolinD,et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473–80.
de LeeuwF, KorfE, BarkhofF, ScheltensP.White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 2006; 37: 2248–52.
EnzingerC, SmithS, FazekasF, et al. Lesion probability maps of white matter hyperintensities in elderly individuals: results of the Austrian stroke prevention study. J Neurol 2006; 253: 1064–70.
EnzingerC, FazekasF, RopeleS, SchmidtR. Progression of cerebral white matter lesions – clinical and radiological considerations. J Neurol Sci 2007; 257: 5–10.
FazekasF, EnglundE. White matter lesions. In: ErkinjunttiT, GauthierS, eds. Vascular Cognitive Impairment. London: Martin Dunitz, 2002; 135–43.
FazekasF, SchmidtR, KleinertR, et al. The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates. J Neural Transm 1998a; 53 (Suppl): S31–9.
FazekasF, SchmidtR, ScheltensP.Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord 1998b; 9(Suppl 1): 2–5.
FazekasF, KleinertR, RoobG, et al. Histopathologic analysis of foci of signal loss in gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. Am J Neuroradiol 1999; 20: 637–42.
FazekasF, RopeleS, EnzingerC, et al. Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult Scler 2002; 8: 479–84.
FazekasF, RopeleS, EnzingerC, et al. MTI of white matter hyperintensities. Brain 2005; 128: 2926–32.
FilippiM.Magnetization transfer MRI in multiple sclerosis and other central nervous system disorders. Eur J Neurol 2003; 10: 3–10.
GardeE, Lykke MortensenE, RostrupE, PaulsonO.Decline in intelligence is associated with progression in white matter hyperintensity volume. J Neurol Neurosurg Psychiatry 2005; 76: 1289–91.
GassA, BarkerG, KiddD, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994; 36: 62–7.
HachinskiV, PotterP, MerskeyH.Leuko-araiosis. Arch Neurol 1987; 44: 21–3.
JeerakathilT, WolfP, BeiserA, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004; 35: 1857–61.
LongstrethW, ArnoldA, BeauchampN, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005; 36: 56–61.
MollerM, FrandsenJ, AndersenG, et al. Dynamic changes of corticospinal tracts after stroke detected by fiber tracking. J Neurol Neurosurg Psychiatry 2007; 78: e-pub.
PantoniL, GarciaJ.The significance of cerebral white matter abnormalities 100 years after Binswanger’s report: a review. Stroke 1995; 26: 1293–301.
PrinsN, van StraatenE, van DijkE, et al. Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004; 62: 1533–39.
PrinsN, Van DijkE, den HeijerT, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005; 128: 2034–41.
RomanG, TatemichiT, ErkinjunttiT, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group. Neurology 1993; 43: 250–60.
RomanG, ErkinjunttiT, WallinA,et al. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426–36.
RopeleS, SeewannA, GouwA, et al. Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis and Disability in the Elderly) study. J Magn Reson Imaging 2008, in press.
SchmidtR, FazekasF, OffenbacherH, et al. Prevalence and risk factors for white matter damage. In: FazekasF, SchmidtR, AlaviA, eds. Neuroimaging of Normal Ageing and Uncommon Causes of Dementia. Dordrecht: ICG Publications, 1998; 11–25.
SchmidtR, FazekasF, KapellerP, et al. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology, 1999; 53: 132–9.
SchmidtR, EnzingerC, RopeleS, et al. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003; 361: 2046–8.
SchmidtR, ScheltensP, ErkinjunttiT, et al. White matter lesion progression: a surrogate endpoint for trials in small-vessel disease. Neurology 2004; 63: 139–44.
SchmidtR, RopeleS, EnzingerC, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention Study. Ann Neurol 2005; 58: 610–16.
SteingartA, HachinskiV, LauC, et al. Cognitive and neurological findings in subjects with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch Neurol 1987; 44: 32–3.
StreiflerJ, EliasziwM, BonaventeO, et al. Development and progression of leukoaraiosis in patients with brain ischemia and carotid artery disease. Stroke 2003; 34: 1913–17.
TaylorW, MacFallJ, ProvenzaleJ, et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. Am J Roentgenol 2003; 181: 571–6.
Ten DamV, van den HeuvelD, van BuchemM,et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005; 64: 1807–09.
Van der FlierW, Van StraatenE, BarkhofF, et al. Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke 2005; 36: 2116–20.
Van DijkE, PrinsN, VermeerS, et al. Frequency of white matter lesions and silent lacunar infarcts. J Neural Transm 2002; 25 (Suppl): 25–39.
Van DijkE, PrinsN, VermeerS, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005; 112: 900–05.
VeldinkJ, ScheltensP, JonkerC, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology 1998; 51: 319–20.
WahlundL, AlmkvistO, BasunH, JulinP.MRI in successful ageing, a 5-year follow-up study from eighth to ninth decade of life. Magn Res Imag 1996; 14: 601–08.
WardlawJ, LewisS, KeirS, et al. Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions. Stroke 2006; 37: 2633–6.
WhitmanG, TangT, LinM, BalohR.A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology 2001; 57: 990–4.
YoshitaM, FletcherE, HarveyD, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006; 67: 2192–8.

References

BaileyTL, RivaraCB, RocherAB, HofPR. The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. Neurol Res 2004; 26: 573–8.
BornebroekM, HaanJ, RoosN. Hereditary cerebral hemorrhage with amyloidosis–Dutch type (HCHWA-D): a review of the variety in phenotypic expression. Amyloid 1999; 6: 215–24.
BrooksWS, KwokJB, HallidayGM, et al. Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology 2004; 63: 1613–17.
CaiXD, Golde, TE, YounkinS. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 1993; 259: 514–16.
CarterDA, DesmaraisE, BellisM, et al. More missense in amyloid gene. Nature Genet, 1992; 2: 255–6.
ChengIH, PalopJJ, EspositoLA, Bien-LyN, YanF, Mucke, L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004; 10: 1190–2.
CitronM, OltersdorfT, HaassC, et al. Mutation of the β-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 1992; 360: 672–4.
CrasP, Van HarskampF, HendriksL, et al. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala →Gly mutation. Acta Neuropathol 1998; 96: 253–60.
DavisJB, CribbsDH, CotmanCW, Van NostrandWE. Pathogenic amyloid beta-protein induces apoptosis in cultured human cerebrovascular smooth muscle. Amyloid Int J Exp Clin Invest 1999; 6: 157–64.
De La TorreJC. Alzheimer’s disease is a vasocognopathy: a new term to describe its nature. Neurol Res 2004; 26: 517–24.
FarkasE, LuitenPGM. Cerebral microvascular pathology in aging and Alzheimer’s disease. Progr Neurobiol 2001; 64: 575–611.
FrangioneB, VidalR, RostagnoA, GhisoJ. Familial cerebral amyloid angiopathies and dementia. Alz Dis Assoc Disord 2000; 14: S25–30.
GarzulyF, VidalR, WisniewskiT, BrittigF, BudkaH. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology 1996; 47: 1562–7.
GhettiB, PiccardoP, SpillantiniMG, et al. Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci USA 1996; 93: 744–8.
GhisoJ, JenssonO, Frangione, B. Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). Proc Natl Acad Sci USA 1986a; 83: 2974–8.
GhisoJ, Pons-EstelB, FrangioneB. Hereditary cerebral amyloid angiopathy: the amyloid contains a protein which is a variant of cystatin C, an inhibitor of lysosomal cysteine proteases. Biochem Biophys Res Comm 1986b; 136: 548–54.
GhisoJ, HaltiaM, PrelliF, NovelloJ, FrangioneB. Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type. Biochem J 1990; 272: 827–30.
GhisoJ, HoltonJ., MiravalleL, et al. Systemic amyloid deposits in Familial British Dementia. J Biol Chem 2001; 276: 43, 909–14.
GhisoJ, FrangioneB. Amyloidosis and Alzheimer’s disease. Adv Drug Delivery Rev 2002; 54: 1539–51.
GhisoJ, VidalR, RostagnoA, et al. Amyloidogenesis in Familial British Dementia is associated with a genetic defect on chromosome 13. In: GrowdonJ, WurtmanR, CorkinS, NitschR, eds. Molecular Basis of Dementia. New York: New York Academy of Sciences, 2000.
GorelickPB. Risk factors for vascular dementia and Alzheimer’s disease. Stroke 2004; 35: 2620–7.
GrabowskiTJ, ChoHS, VonsattelJPG, RebeckGW, GreenbergSM. A novel APP mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001; 49: 697–705.
GreenbergSM, ShinY, GrabowskiTJ, et al. Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology 2003; 60: 1020–2.
GudmundssonG, HallgrimssonJ, JonassonT, BjarnasonO. Hereditary cerebral hemorrhage with amyloidosis. Brain 1972; 95: 387–404.
HaltiaM, GhisoJ, PrelliF, et al. Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin. Am J Pathol 1990a; 136: 223–8.
HaltiaM, PrelliF, GhisoJ, et al. Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsolin, an actin-binding protein. Biochem Biophys Res Comm 1990b; 176: 927–32.
HendriksL, Van DuijnCM, CrasP, et al. Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genetics 1992; 1: 218–21.
HerzigMC, WinklerDT, BurgermeisterP, et al. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neurosci 2004; 7: 954–60.
HoltonJ, GhisoJ, LashleyT, et al. Regional distribution of fibrillar and non-fibrillar ABri deposition and its association with neurofibrillary degeneration in Familial British Dementia. Am J Pathol 2001; 158: 515–26.
HoltonJ, LashleyT, GhisoJ, et al. Familial Danish Dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol 2002; 61: 254–67.
IglesiasS, ChaponF, BaronJC. Familial occipital calcifications, hemorrhagic strokes, leukoencephalopathy, dementia, and external carotid dysplasia. Neurology 2000; 55: 1661–7.
JanowskiR, AbrahamsonM, GrubbA, JaskolskiM. Domain swapping in N-truncated cystatin C. J Mol Biol 2004; 341: 151–60.
JanowskiR, KozakM, AbrahamsonM, GrubbA, JaskolskiM. 3D domain-swapped human cystatin C with amyloid-like intermolecular-sheets. Structure Funct Bioinform 2005; 61: 570–8.
JanowskiR, KozakM, JankowskaE, et al. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol 2001; 8: 316–20.
KaminoK, OrrHT, PayamiH, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 1992; 51: 998–1014.
KangI, LemaireHG, UnterbeckA, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733–6.
KiuruS. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 1998; 5: 55–66.
Kumar-SinghS, CrasP, WangR, et al. Dense-core senile plaques in the Flemish variant of Alzheimer’s disease are vasocentric. Am J Pathol 2002; 161: 507–20.
Kumar-SinghS, Lopez-OtinC, GhisoJ, GeltnerD, FrangioneB. Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. J Exp Med 1989; 169: 1771–8.
Kumar-SinghS, CarmanMD, Fernandez MadridIJ, et al. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990a; 248: 1124–6.
Kumar-SinghS, HaltiaM, Fernandez-MadridI, et al. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 1990b; 172: 1865–7.
Kumar-SinghS, JascolskiM, GrubbA. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 2006; 16: 60–70.
Maat-SchiemanM, YamaguchiH, Van DuinenS, NatteR, RoosRA. Age-related plaque morphology and C-terminal heterogeneity of amyloid β in Dutch-type hereditary cerebral hemorrhage with amyloidosis. Acta Neuropathol 2000; 99: 409–19.
Maat-SchiemanM, YamaguchiH, Hegeman-KleinnIM, et al. Glial reactions and the clearance of amyloid β protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Acta Neuropathol 2004; 107: 389–98.
MastersCL, SimmsG, WeinmanNA,MulthaupG, McdonaldBL, BeyreutherK. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245–9.
MelchorJP, Van NostrandWE. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J Biol Chem 2000; 275: 9782–91.
MiravalleL, TokudaT, ChiarleR, et al. Substitution at codon 22 of Alzheimer’s Aβ peptide induces diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000; 275: 27, 110–16.
MullanM, CrawfordF, AxelmanK, et al. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of β-amyloid. Nature Genet 1992; 1: 345–7.
NatteR, Maat-SchiemanM, HaanJ, BornebroekM, RoosR, Van DuinenS. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 2001; 50: 765–72.
NilsberthC, Westlind-DanielssonA, EckmanCB, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4: 887–93.
NochlinD, BirdTD, NemensE, BallMJ, SumiSM. Amyloid angiopathy in a Volga German family with Alzheimer’s disease and a presenilin-2 mutation (N141I). Ann Neurol 1998; 43: 131–5.
ObiciL, DemarchiA, De RosaG, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 2005; 58: 639–44.
PanKM, BaldwinM, NguyenJ, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993; 90: 10962–6.
PetersenRB, GorenH, CohenM, et al. Transthyretin amyloids: a new mutation associated with dementia. Ann Neurol 1997; 41: 307–13.
PettyMA, WettsteinJG. Elements of cerebral microvascular ischaemia. Brain Res Rev 2001; 36: 23–34.
ReveszT, GhisoJ, LashleyT, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003; 62: 885–98.
RossiG, GiacconeG, MalettaR, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 2004; 63: 910–12.
RostagnoA, GhisoJ. Amyloidosis. In: AminoffM, DaroffR, eds. Encyclopedia of Neurological Sciences. San Diego: Academic Press, 2003.
RostagnoA, TomidokoroY, LashleyT, et al. Chromosome 13 dementias. Cell Mol Life Sci 2005; 62: 1814–25.
RussoC, SaidoTC, DebuskLM, TabatonM, GambettiP, TellerJK. Heterogeneity of water-soluble amyloid b-peptide in Alzheimer’s disease and Down’s syndrome brains. FEBS Lett 1997; 409: 411–16.
RussoC, ViolaniE, SalisS, et al. Pyroglutamate-modified amyloid β-peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival. J Neurochem 2002; 82: 1480–9.
SaidoT, IwatsuboT, MannDM, ShimadaH, IharaY, KawashimaS. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 1995; 14: 457–66.
SakashitaN, AndoY, JinnouchiK, et al. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 2001; 51: 476–80.
SchillingS, LauberT, SchauppM, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006; 45: 12394–9.
SelkoeD. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 1999; 399: 23–31.
ShinY, ChoHS, RebeckGW, GreenbergBD. Vascular changes in Iowa-type hereditary cerebral amyloid angiopathy. Ann NY Acad Sci 2002; 977: 245–51.
ShinY, ChoHS, FukumotoH, et al. Abeta species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy. Acta Neuropathol 2003; 105: 252–8.
SteinerH, ReveszT, NeumannM, et al. A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. J Biol Chem 2001; 276: 7233–39.
StenhC, NilsberthC, HammarbackJ, EngvallB, NaslundJ, LannfeltL. The Arctic mutation interferes with processing of the amyloid precursor protein. Neuro Report 2002; 13: 1857–60.
SuzukiN, CheungTT, CaiXD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (APP717) mutants. Science 1994; 264: 1336–40.
TomidokoroY, LashleyT, RostagnoA, et al. Familial Danish dementia: co-existence of ADan and Aβ amyloid subunits in the absence of compact plaques. J Biol Chem 2005; 280: 36883–94.
WakutaniY, WatanabeK, AdachiY, et al. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1039–42.
WalshDM, LomakinA, BenedekGB, CondronMM, TeplowD.Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997; 272: 22364–72.
WalshDM, HartleyDM, CondronMM, SelkoeDJ, TeplowDB. In vitro studies of amyloid b-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692 → Gly) Alzheimer’s disease. Biochem J 2001; 355: 869–77.
Van NostrandWE, MelchorJP, ChoHS, GreenbergSM, RebeckGW. Pathogenic effects of D23N Iowa mutant amyloid β-protein. J Biol Chem 2001; 276: 32860–6.
VidalR, GarzulyF, BudkaH, et al. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol 1996; 148: 351–4.
VidalR, FrangioneB, RostagnoA, MeadS, ReveszT, PlantG, GhisoJ.A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999; 399: 776–81.
VidalR, GhisoJ, ReveszT, et al. A decamer duplication in the 3′ region of the BRI gene originates a new amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA 2000; 97: 4920–5.
Worster-DroughtC, HillT, McMenemeyW. Familial presenile dementia with spastic paralysis. J Neurol Psychopathol 1933; 14: 27–34.
Zhang-NunesSX, Maat-SchiemanM, Van DuinenS, RoosR, FroschMP, GreenbergSM.The cerebral β-amyloid angiopathies: Hereditary and sporadic. Brain Pathol 2006; 16: 30–9.

References

Agüero-TorresH, KivipeltoM, von StraussE. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dementia Geriat Cogn Disord 2006; 22: 244–9.
AnttilaT, HelkalaEL, ViitanenM, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. Br Med J 2004; 329: 539–42.
BalkEM, RamanG, TatsioniA, ChungM, LauJ, RosenbergIH. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Int Med 2007; 167: 21–30.
BiesselsGJ, StaekenborgS, BrunnerE, BrayneC, ScheltensP. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.
CordonnierC, van der FlierWM, SluimerJD, LeysD, BarkhofF, ScheltensP. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356–60.
CoreaF, HenonH, PasquierF, LeysD. Silent infarcts in stroke patients: patient characteristics and effect on 2-year outcome. J Neurol 2001; 248: 271–8.
DollR, PetoR, BorehamJ, SutherlandI. Smoking and dementia in male British doctors: prospective study. Br Med J 2000; 320: 1097–102.
EtminanM, GillS, SamiiA. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. Br Med J 2003; 327: 128–31.
FirbankMJ, BurtonEJ, BarberR, et al. Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiol Aging 2007; 28: 1664–9.
FratiglioniL, Paillard-BorgS, WinbladB. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3: 343–53.
FratiglioniL, von StraussE, QiuCX. Epidemiology of the dementias of old age. In: DeningT, JacobyR, OppenheimerC, ThomasA, eds. The Oxford Textbook of Old Age Psychiatry, 4th edn., New York: Oxford University Press, 2008; 391–406.
GamaldoA, MoghekarA, KiladaS, ResnickSM, ZondermanAB, O’BrienR. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 2006; 67: 1363–9.
GorospeEC, DaveJK. The risk of dementia with increased body mass index. Age Ageing 2007; 36: 23–9.
GustafsonD. Adiposity indices and dementia. Lancet Neurol 2006; 5: 713–20.
HaglundM, PassantU, SjobeckM, GhebremedhinE, EnglundE. Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int J Geriatr Psychiatry 2006; 21: 681–7.
InzitariD, SimoniM, PracucciG, et al. for the LADIS Study Group. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS Study. Arch Int Med 2007; 167: 81–8.
KalmijnS, FoleyD, WhiteL, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu–Asia Aging Study. Arterioscler Thromb Vasc Biol 2000; 20: 2255–60.
KarpA, Paillard-BorgS, WangH-X, SilversteinM, WinbladB, FratiglioniL. Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dementia Geriatr Cogn Disord 2006; 21: 65–73.
KivipeltoM, NganduT, LaatikainenT, WinbladB, SoininenH, TuomilehtoJ. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5: 735–41.
KorfES, van StraatenEC, de LeeuwFE, et al. for the LADIS Study Group. Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS Study. Diabetic Med 2007; 24: 166–71.
KullerLH, LopezOL, JagustWJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 2005; 64: 1548–52.
LangaKM, FosterNL, LarsonEB. Mixed dementia: emerging concepts and therapeutic implications. J Am Med Ass 2004; 292: 2901–08.
LarsonEB, WangL, BowenJD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Int Med 2006; 144: 73–81.
LaunerLJ, RossGW, PetrovitchH, et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging 2000; 21: 49–55.
LeysD, HenonH, Mackowiak-CordolianiMA, PasquierF. Poststroke dementia. Lancet Neurol 2005; 4: 752–9.
LongstrethWT, ArnoldAM, BeauchampNJ, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005; 36: 56–61.
MitnitskiA, SkoogI, SongX, et al. A vascular risk factor index in relation to mortality and incident dementia. Eur J Neurol 2006; 13: 514–21.
MoroneyJT, TangMX, BerglundL, et al. Low-density lipoprotein cholesterol and risk of dementia with stroke. J Am Med Ass 1999; 282: 254–60.
OnyikeCU. Cerebrovascular disease and dementia. Int Rev Psychiatry 2006; 18: 423–31.
PurandareN, BurnsA, DalyKJ, et al. Cerebral emboli as a potential cause of Alzheimer’s disease and vascular dementia: case-control study. Br Med J 2006; 332: 1119–24.
QiuC, WinbladB, FratiglioniL. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–99.
QiuC, WinbladB, MarengoniA, KlarinI, FastbomJ, FratiglioniL. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Int Med 2006; 166: 1003–08.
QiuC, SkoogI, FratiglioniL. Occurrence and determinants of vascular cognitive impairment. In: ErkinjunttiT, GauthierS, eds. Vascular Cognitive Impairment. London: Martin Dunitz Ltd, 2002; 61–83.
RovioS, KåreholtI, HelkalaEL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol 2005; 4: 705–11.
SelnesOA, VintersHV. Vascular cognitive impairment. Nature Clin Pract Neurol 2006; 2: 538–47.
SeshadriS, WolfPA, BeiserA, et al. Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology 2004; 63: 1591–9.
TzourioC, AndersonC, ChapmanN, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med 2003; 163: 1069–75.
van der FlierWM, van StraatenEC, BarkhofF, et al. for the LADIS Study Group. Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS Study. J Neurol Neurosurg Psychiatry 2005; 76: 1497–500.
VermeerSE, PrinsND, den HeijerT, HofmanA, KoudstaalPJ, BretelerMM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–22.
ViitanenM, KalimoH. CADASIL: hereditary arteriopathy leading to multiple brain infarcts and dementia. Ann NY Acad Sci 2000; 903: 273–84.
WangH-X, FratiglioniL, FrisoniGB, ViitanenM, WinbladB. Smoking and the occurrence of Alzheimer’s disease: cross-sectional and longitudinal data in a population-based study. Am J Epidemiol 1999; 149: 640–4.
XuW, QiuC, WinbladB, FratiglioniL. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 2007; 56: 211–16.
YaffeK, KanayaA, LindquistK, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. J Am Med Ass 2004; 292: 2237–42.
ZhuL, FratiglioniL, GuoZ, WinbladB, ViitanenM. Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project. Neurology 2000; 54: 2103–07.

References

AronsonMK, OoiWL, MorgensternH, et al. Women, myocardial infarction, and dementia in the very old. Neurology 1990; 40: 1102–06.
BanY, WatanabeT, MiyazakiA, et al. Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis 2006; 195(1): 153–9.
BarberM, TaitRC, ScottJ, RumleyA, LoweGD, StottDJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost 2004; 2: 1873–8.
BeachTG, WilsonJR, SueLI, et al. Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (Berl) 2007; 113: 13–21.
BernardSA, GrayTW, BuistMD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346: 557–63.
BorensteinAR, WuY, MortimerJA, et al. Developmental and vascular risk factors for Alzheimer’s disease. Neurobiol Aging 2005; 26: 325–34.
BrookmeyerR, GrayS, KawasC. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Pub Hlth 1998; 88: 1337–42.
BustoR, GlobusMY, DietrichWD, MartinezE, ValdesI, GinsbergMD. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain. Stroke 1989; 20: 904–10.
CorderEH, SaundersAM, RischNJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 1994; 7: 180–4.
DiCarlo A, BaldereschiM, AmaducciL, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Geriatr Soc 2000; 48: 775–82.
EckenhoffRG, JohanssonJS, WeiH, et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004; 101: 703–09.
EliasMF, SullivanLM, EliasPK, et al. Atrial fibrillation and cognitive performance in the Framingham offspring men. Int J Stroke Cardiovasc Dis 2006; 15: 214–22.
FelderRB, FrancisJ, ZhangZH, WeiSG, WeissRM, JohnsonAK. Heart failure and the brain: new perspectives. Am J Physiol Regul Integr Comp Physiol 2003; 284: R259–76.
ForetteF, SeuxML, StaessenJA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51.
FortiP, MaioliF, PisacaneN, RiettiE, MontesiF, RavagliaG. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment. Neurol Res 2006; 28: 625–9.
FreudenbergerRS, MassieBM. Silent cerebral infarction in heart failure: vascular or thromboembolic?J Cardiac Fail 2005; 11: 490–1.
FriesJF. Aging, natural death, and the compression of morbidity. N Engl J Med 1980; 303: 130–5.
GruhnN, LarsenFS, BoesgaardS, et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001; 32: 2530–3.
HaydenKM, ZandiPP, LyketsosCG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006; 20: 93–100.
HébertSS, SerneelsL, DejaegereT, et al. Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis 2004; 17: 260–72.
HofmanA, OttA, BretelerMM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997; 349: 151–4.
HonigLS, KukullW, MayeuxR. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology 2005; 64: 494–500.
HornM, SchloteW, HenrichHA. Global cerebral ischemia and subsequent selective hypothermia. A neuropathological and morphometrical study on ischemic neuronal damage in cat. Acta Neuropathol (Berl) 1991; 81: 443–9.
HorstedTI, RasmussenLS, MeyhoffCS, NielsenSL. Long-term prognosis after out-of-hospital cardiac arrest. Resuscitation 2007; 72: 214–18.
Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346: 549–56.
JeffersonAL, PoppasA, PaulRH, CohenRA. Systemic hypoperfusion is associated with executive dysfunction in geriatric cardiac patients. Neurobiol Aging 2007; 28: 477–83.
KhachaturianAS, ZandiPP, LyketsosCG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686–92.
KilanderL, AndrenB, NymanH, LindL, BobergM, LithellH. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998; 29: 1816–20.
KivipeltoM, NganduT, FratiglioniL, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556–60.
KnopmanDS, PetersenRC, ChaRH, EdlandSD, RoccaWA. Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease. Neurology 2005; 65: 986–90.
KosunenO, TalasniemiS, LehtovirtaM, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 1995; 26: 743–8.
LeeTA, WolozinB, WeissKB, BednarMM. Assessment of the emergence of Alzheimer’s disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheim Dis 2005; 7: 319–24.
LeonovY, SterzF, SafarP, et al. Mild cerebral hypothermia during and after cardiac arrest improves neurologic outcome in dogs. J Cerebr Blood Flow Metab 1990; 10: 57–70.
LiD, ParksSB, KushnerJD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am J Hum Genet 2006; 79: 1030–9.
LimA, TsuangD, KukullW, et al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999; 47: 564–9.
LuchsingerJA, ReitzC, HonigLS, TangMX, SheaS, MayeuxR. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545–51.
MarianiE, PolidoriMC, CherubiniA, MecocciP. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B, Analyt Technol Biomed Life Sci 2005; 827: 65–75.
MarionDW, LeonovY, GinsbergM, et al. Resuscitative hypothermia. Crit Care Med 1996; 24: S81–9.
McKhannGM, GregaMA, BorowiczLM Jr, et al. Is there cognitive decline 1 year after CABG? Comparison with surgical and nonsurgical controls. Neurology 2005; 65: 991–9.
MensahGA, MokdadAH, FordES, GreenlundKJ, CroftJB. State of disparities in cardiovascular health in the United States. Circulation 2005; 111: 1233–41.
MüllgesW, Babin-EbellJ, ReentsW, ToykaKV. Cognitive performance after coronary artery bypass grafting: a follow-up study. Neurology 2002; 59: 741–3.
NapoliC, PalinskiW. Neurodegenerative diseases: insights into pathogenic mechanisms from atherosclerosis. Neurobiol Aging 2005; 26: 293–302.
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 357: 169–75.
NewmanAB, FitzpatrickAL, LopezO, et al. Dementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005; 53: 1101–07.
NewmanMF, KirchnerJL, Phillips-ButeB, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Eng J Med 2001a; 344: 395–402.
NewmanMF, LaskowitzDT, WhiteWD, et al. Apolipoprotein E polymorphisms and age at first coronary artery bypass graft. Anesth Analg 2001b; 92: 824–9.
NielsenJR, GramL, RasmussenLP, et al. Intellectual and social function of patients surviving cardiac arrest outside the hospital. Acta Med Scand 1983; 213: 37–9.
OkuK, KuboyamaK, SafarP, et al. Cerebral and systemic arteriovenous oxygen monitoring after cardiac arrest. Inadequate cerebral oxygen delivery. Resuscitation 1994; 27: 141–52.
OttA, BretelerMM, de BruyneMC, van HarskampF, GrobbeeDE, HofmanA. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316–21.
ParkHL, HildrethAJ, ThomsonRG, O’ConnellJ. Non-valvular atrial fibrillation and cognitive function – baseline results of a longitudinal cohort study. Age Ageing 2005; 34: 392–5.
ParkH, HildrethA, ThomsonR, O’ConnellJ. Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study. Age Ageing 2007; 36: 157–63.
PatelRL, TurtleMR, ChambersDJ, NewmanS, VennGE. Hyperperfusion and cerebral dysfunction. Effect of differing acid–base management during cardiopulmonary bypass. Eur J Cardiothor Surg 1993; 7: 457–63; discussion, 464.
PetersenP, KastrupJ, VidebaekR, BoysenG. Cerebral blood flow before and after cardioversion of atrial fibrillation. J Cerebr Blood Flow Metab 1989; 9: 422–5.
PlutaR. The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemia–reperfusion brain injury. A model of early Alzheimer’s disease. Ann NY Acad Sci 2000; 903: 324–34.
PutzkeJD, WilliamsMA, RayburnBK, KirklinJK, BollTJ. The relationship between cardiac function and neuropsychological status among heart transplant candidates. J Cardiac Fail 1998; 4: 295–303.
QiuC, WinbladB, MarengoniA, KlarinI, FastbomJ, FratiglioniL. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Int Med 2006; 166: 1003–08.
RamlawiB, RudolphJL, MienoS, et al. Serologic markers of brain injury and cognitive function after cardiopulmonary bypass. Ann Surg 2006; 244: 593–601.
RavagliaG, FortiP, MaioliF, et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dementia Geriatr Cogn Disord 2006; 21: 51–8.
RossGW, PetrovitchH, WhiteLR, et al. Characterization of risk factors for vascular dementia: the Honolulu–Asia Aging Study. Neurology 1999; 53: 337–43.
SamuelsMA. Can cognition survive heart surgery?Circulation 2006; 113: 2784–6.
SanbeA, OsinskaH, VillaC, et al. Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci USA 2005; 102: 13592–7.
SavageauJA, StantonBA, JenkinsCD, FraterRW. Neuropsychological dysfunction following elective cardiac operation. II. A six-month reassessment. J Thorac Cardiovasc Surg 1982; 84: 595–600.
SchmidtR, SchmidtH, FazekasF. Vascular risk factors in dementia. J Neurol 2000; 247: 81–7.
SendelbachS, LindquistR, WatanukiS, SavikK. Correlates of neurocognitive function of patients after off-pump coronary artery bypass surgery. Am J Crit Care 2006; 15: 290–8.
SlooterAJ, van DuijnCM, BotsML, et al. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Supplem 1998; 53: 17–29.
SlooterAJ, CrutsM, HofmanA, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology 2004; 62: 1196–8.
StanleyTO, MackensenGB, GrocottHP, et al. The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass graft surgery. Anesth Analg 2002; 94: 290–5.
ThomT, HaaseN, RosamondW, et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85–151.
TreschDD, FolsteinMF, RabinsPV, HazzardWR. Prevalence and significance of cardiovascular disease and hypertension in elderly patients with dementia and depression. J Am Geriatr Soc 1985; 33: 530–7.
TrojanoL, AntonelliIncalzi R, AcanforaD, PiconeC, MecocciP, RengoF. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol 2003; 250: 1456–63.
van der CammenTJ, VerschoorCJ, van LoonCP, et al. Risk of left ventricular dysfunction in patients with probable Alzheimer’s disease with APOE*4 allele. J Am Geriatr Soc 1998; 46: 962–7.
van DijkD, SpoorM, HijmanR, et al. Cognitive and cardiac outcomes 5 years after off-pump vs. on-pump coronary artery bypass graft surgery. J Am Med Assoc 2007; 297: 701–08.
WannBP, BahTM, BoucherM, et al. Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: a possible model for human postinfarct major depression. J Psychiatry Neurosci 2007; 32: 11–16.
WatanabeT, KobaS, KawamuraM, et al. Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. Metabolism 2004; 53: 476–82.
WilsonPW, HoegJM, D’AgostinoRB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 1997; 337: 516–22.
WisniewskiHM, MaslinskaD. Beta-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol 1996; 34: 65–71.
WitykRJ, GoldsboroughMA, HillisA, et al. Diffusion- and perfusion-weighted brain magnetic resonance imaging in patients with neurologic complications after cardiac surgery. Arch Neurol 2001; 58: 571–6.
XieZ, DongY, MaedaU, et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 2006; 104: 988–94.
ZuccalaG, CattelC, Manes-GravinaE, DiNiro MG, CocchiA, BernabeiR. Left ventricular dysfunction: a clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997; 63: 509–12.
ZuccalaG, OnderG, PedoneC, et al. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology 2001; 57: 1986–92.

References

Aguero-TorresH, KivipeltoM, von StraussE.Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dementia Geriatr Cogn Disord 2006; 22: 244–9.
BerchtoldNC, KesslakJP, CotmanCW. Hippocampal brain-derived neurotrophic factor gene regulation by exercise and the medial septum. J Neurosci Res 2002; 68: 511–21.
BjörkhemI.Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Int Med 2006; 260: 493–508.
CalonF, LimGP, YangF, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 2004; 43(5): 633–45.
Cedazo-MinguezA, CowburnRF. Apolipoprotein E: a major piece in the Alzheimer’s disease puzzle. J Cell Mol Med 2001; 5: 254–66.
Colcombe, SJ, Kramer, AF, Erickson, KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA 2004; 101(9): 3316–21.
de la TorreJC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152–62.
DingJ, EigenbrodtML, MosleyTH Jr, et al. Alcohol intake and cerebral abnormalities on magnetic resonance imaging in a community-based population of middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2004; 35(1): 16–21.
FratiglioniL, Paillard-BorgS, WinbladB. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3(6): 343–53.
Freund-LeviY, Eriksdotter-JonhagenM, CederholmT, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63(10): 1402–08.
GiannakopoulosP, GoldG, KovariE, et al. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol (Berl) 2007; 113(1): 1–12.
GirouardH, IadecolaC.Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006; 100(1): 328–35.
GustafsonD, RothenbergE, BlennowK, SteenB, SkoogI. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003; 163: 1524–8.
HonigLS, KukullW, MayeuxR. Atherosclerosis and AD. Analysis of data from the US National Alzheimer’s Coordinating Center. Neurology 2005; 64: 494–500.
JellingerKA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007; 113(4): 349–88.
KalariaRN. Overlap with Alzheimer’s disease. In: Erkinjuntti T, Gauthiers, eds. Vascular Cognitive Impairment. London: Martin Dunitz Ltd, 2002.
KalariaRN, BallardC. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; Oct–Dec; 13 Suppl 3: S115–23.
KivipeltoM, HelkalaE-L, LaaksoMP, et al. Apolipoprotein E ε4 allele, elevated midlife total cholesterol level and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer’s disease. Ann Intern Med 2002; 137: 149–55.
KivipeltoM, NganduT, FratiglioniL, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer’s disease. Arch Neurol 2005; 62: 1556–60.
KivipeltoM, NganduT, LaatikainenT, WinbladB, SoininenH, TuomilehtoJ. Risk score for prediction of dementia risk in 20 years among middle aged people: a longitudinal population based study. Lancet Neurol 2006; 9: 735–41.
KramerA, HahnS, CohenNJ, et al. Ageing, fitness and neurocognitive function. Nature 1999; 400: 418–19.
LaitinenM, NganduT, RovioS, et al. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord 2006; 22: 99–107.
LaunerLJ, RossGW, PetrovitchH, et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging 2000; 21: 49–55.
LaunerLJ, WhiteLR, PetrovitchH, RossGW, CurbJD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001; 57: 1447–52.
LibonDJ, PriceCC, HeilmanKM, GrossmanM. Alzheimer’s ‘other dementia’. Cognit Behav Neurol 2006; 19: 112–16.
LuchsingerJA, MayeuxR. Dietary factors and AD. Lancet Neurol, 2004; 3: 579–87.
MartinsIJ, HoneE, FosterJK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Molec Psychiatry 2006; 11: 721–36.
MukamalKJ, LongstrethWT Jr, MittlemanMA, CrumRM, SiscovickDS. Alcohol consumption and subclinical findings on magnetic resonance imaging of the brain in older adults: the cardiovascular health study. Stroke 2001; 32(9): 1939–46.
OksmanM, IivonenH, HogyesE, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23(3): 563–72.
PappollaMA, Bryant-ThomasTK, HerbertD, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003; 61(2): 199–205.
PeilaR, WhiteLR, MasakiK, PetrovitchH, LaunerLJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006; 37(5): 1165–70.
QiuWQ, FolsteinMF. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 2006; 27: 190–8.
RomanGC, KalariaRN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27: 1769–85.
RockwoodK. The mixed dementias. In: Erkinjuntti T, Gauthiers, eds. Vascular Cognitive Impairment. London: Martin Dunitz Ltd, 2002.
RockwoodK.Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer’s disease. Acta Neurol Scand Suppl 2006; 185: 71–7.
RovioS, KåreholtI, HelkalaE-L, et al. Leisure time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol 2005; 4: 705–10.
ScarmeasN, SternY, MayeuxR, LuchsingerJA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 2006; 63(12): 1709–17.
SkoogI, LernfeltB, LandahlS, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.
SimonsM, SchwarzlerF, LutjohannD, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346–50.
SnowdonDA, GreinerLH, MortimerJA, et al. Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997; 277: 813–17.
SolomonA, KåreholtI, NganduT, et al. Serum cholesterol changes after midlife and late-life cognition: 21-year follow-up study. Neurology 2007; 68(10): 751–6.
SparksDL, ScheffSW, HunsakerJC 3rd, LiuH, LandersT, GrossDR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126(1): 88–94.
SparksDL, SabbaghMN, ConnorDJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753–7.
StewartR, WhiteLR, XueQL, LaunerLJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu–Asia Aging Study. Arch Neurol 2007; 64(1): 103–07.
TongL, ShenH, PerreauVM, BalazsR, CotmanCW. Effects of exercise on gene-expression profile in the rat hippocampus. Neurobiol Dis 2001; 8: 1046–56.
WhitmerRA, SidneyS, SelbyJ, JohnstonSC, YaffeK.Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64(2): 277–81.